Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595

References

• Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901–1911.
   PubMed Web of Science ®Google Scholar
• Conlon R, Saheb H, Ahmed II. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017;52:114–124.
   PubMed Web of Science ®Google Scholar
• Lewis CJ, Hedberg-Buenz A, DeLuca AP, et al. Primary congenital and developmental glaucomas. Hum Mol Genet. 2017;26(R1):R28–Z36.
   PubMed Web of Science ®Google Scholar
• Kwon YH, Fingert JH, Kuehn MH, et al. Primary open-angle glaucoma. N Engl J Med. 2009;360:1113–1124.
   PubMed Web of Science ®Google Scholar
• Yadav KS, Rajpurohit R, Sharma S. Glaucoma: current treatment and impact of advanced drug delivery systems. Life Sci. 2019;221:362–376.
   PubMed Web of Science ®Google Scholar
• Vicente A, Prud’homme S, Ferreira J, et al. Open-angle glaucoma: drug development pipeline during the last 20 years (1995–2015). Ophthalmic Res. 2017;57:201–207.
   PubMed Web of Science ®Google Scholar
• Lazreg S, Merad Z, Nouri MT, et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications. J Fr Ophtalmol. 2018;41:945–954.
   PubMed Web of Science ®Google Scholar
• Hathout RM, Gad HA, Abdel-Hafez SM, et al. Gelatinized core liposomes: A new trojan horse for the development of a novel timolol maleate glaucoma medication. Int J Pharm. 2019;556:192–199.
   PubMedGoogle Scholar
• Negri L, Ferreras A, Lester M. Timolol 0.1% in glaucomatous patients: efficacy, tolerance, and quality of life. J Ophthalmol. 2019;1-12. published online May 2. doi:10.1155/2019/4146124
   Web of Science ®Google Scholar
• Kurysheva NI. Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination. Taiwan J Ophthalmol. 2019;9:93–99.
   PubMedGoogle Scholar
• Duru Z, Özsaygılı C, Ulusoy DM, et al. Does using topical latanoprost affect subfoveal choroidal thickness? Cutan Ocul Toxicol. 2019;1–5. published online Jun 18. doi:10.1080/15569527.2019.1632884
   Web of Science ®Google Scholar
• Becker B. The mechanism of the fall in intraocular pressure by the carbonic anhydrase inhibitor diamox. Am J Ophthalmol. 1955;39:177–183.
   PubMed Web of Science ®Google Scholar
• Kinsey VE, Reddy DVN. Turnover of total carbon dioxide in aqueous humors and the effect thereon of acetazolamide. Arch Ophthalmol. 1959;62:78–83.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat. 2000;10:575–600.
   Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett. 2010;20:3467–3474.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets. Curr Pharm Des. 2010;16:3233–3245.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev. 2003;23:146–189.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem. 2014;75:349–359.
   PubMedGoogle Scholar
• Costagliola C, Parmeggiani F, Ciancaglini M, et al. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Ophthalmologica. 2003;217:39–44.
   PubMed Web of Science ®Google Scholar
• Chen TC. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery. J Cataract Refract Surg. 2005;31:1707–1712.
   PubMed Web of Science ®Google Scholar
• Oatts JT, Wang X, Loewen NA. Effect of alpha-2-agonist premedication on intraocular pressure after selective laser trabeculoplasty. Indian J Ophthalmol. 2015;63:891–894.
   PubMed Web of Science ®Google Scholar
• Faiq MA, Wollstein G, Schuman JS, et al. Cholinergic nervous system and glaucoma: from basic science to clinical applications. Prog Retin Eye Res. 2019: published online Jun 23. DOI:10.1016/j.preteyeres.2019.06.003.
   PubMed Web of Science ®Google Scholar
• Costa CM, Louvisse de Abreu LC, Dos Santos EP, et al. Preparation and evaluation of chitosan submicroparticles containing pilocarpine for glaucoma therapy. Curr Drug Deliv. 2015;12:491–503.
   PubMed Web of Science ®Google Scholar
• Sato S, Hirooka K, Nitta E, et al. Additive intraocular pressure lowering effects of the rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33:1628–1634.
   PubMed Web of Science ®Google Scholar
• Inazaki H, Kobayashi S, Anzai Y, et al. Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy. J Glaucoma. 2017;26:96–100.
   PubMed Web of Science ®Google Scholar
• Inazaki H, Kobayashi S, Anzai Y, et al. One-year efficacy of adjunctive use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol. 2017;255:2009–2015.
   PubMed Web of Science ®Google Scholar
• Tanna AP, Johnson M. Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension. Ophthalmolol. 2018;125:1741–1756.
   PubMed Web of Science ®Google Scholar
• Liljebris C, Selen G, Resul B, et al. Derivatives of 17-phenyl-18,19,20-trinorprostaglandin F2 isopropyl ester: potential anti-glaucoma agents. J Med Chem. 1995;38:289–304.
   PubMed Web of Science ®Google Scholar
• Blakely RD, DeFelice LJ, Galli A. Biogenic amine neurotransmitter transporters: just when you thought you knew them. Physiol. 2005;20:225–231.
   PubMed Web of Science ®Google Scholar
• Feng Y, LoGrasso PV, Defert O, et al. Rho Kinase (ROCK) inhibitors and their therapeutic potential. J Med Chem. 2016;59:2269–2300.
   PubMed Web of Science ®Google Scholar